Austrian hospitals onboard Sophia Genetics for blood cancer diagnostics

Sequencing Dna Rna Social

Austria's second-largest hospital has gone live with the Sophia DDM next-generation sequencing (NGS) platform for diagnosing blood-related cancers, Sophia Genetics announced.

Kepler Uniklinikum, an 1,800-bed hospital in Upper Austria, will implement Sophia's DDM genetic testing platform across Kepler's medical and central laboratory locations.

The Sophia DDM Platform uses NGS to target key variants from formalin fixation and paraffin-embedding (FFPE), blood, or bone marrow samples, according to Sophia Genetics. The platform is specifically designed to compute a wide array of genomic variants and employs machine-learning algorithms to detect genomic variants associated with rare and challenging cases.

"The testing will not only help the local population but will provide valuable insights and data to support others using the Sophia DDM Platform around the world," said Kevin Puylaert, a managing director at Sophia Genetics.

The Kepler announcement follows another in May in relation to Austria's Klinikum Klagenfurt am Wörthersee's implementation. Another large hospital, Klinikum Klagenfurt am Wörthersee is also home to the Institute for Laboratory Diagnostics and Microbiology (ILM) and serves more than half a million patients annually, as well as patients at neighboring hospitals throughout the state of Carinthia.

Klinikum Klagenfurt am Wörthersee will use the Sophia DDM Platform for solid tumor and blood cancer (hematology oncology) samples. Sophia Genetics added that the hospital will retain complete ownership of its database.

In Austria, some 42,000 people are diagnosed with cancer each year, Sophia Genetics noted in its announcement.

Page 1 of 39
Next Page